Concepts (152)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urology | 7 | 2019 | 15 | 2.280 |
Why?
|
| Malpractice | 5 | 2015 | 10 | 1.530 |
Why?
|
| Prostatic Neoplasms | 8 | 2019 | 92 | 1.020 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2019 | 162 | 0.790 |
Why?
|
| Clinical Competence | 2 | 2015 | 189 | 0.780 |
Why?
|
| Prostate | 6 | 2019 | 30 | 0.690 |
Why?
|
| Urinary Bladder Neoplasms | 3 | 2012 | 34 | 0.620 |
Why?
|
| Kidney Neoplasms | 4 | 2018 | 75 | 0.610 |
Why?
|
| Vena Cava, Inferior | 1 | 2019 | 9 | 0.600 |
Why?
|
| Ureteral Neoplasms | 1 | 2019 | 5 | 0.600 |
Why?
|
| Carcinoma, Renal Cell | 3 | 2018 | 45 | 0.590 |
Why?
|
| SEER Program | 4 | 2013 | 34 | 0.580 |
Why?
|
| Ureteroscopy | 1 | 2018 | 8 | 0.570 |
Why?
|
| Kidney Calculi | 1 | 2018 | 6 | 0.570 |
Why?
|
| Ureteral Calculi | 1 | 2018 | 7 | 0.570 |
Why?
|
| Simulation Training | 2 | 2019 | 34 | 0.550 |
Why?
|
| Stents | 1 | 2018 | 75 | 0.540 |
Why?
|
| Internship and Residency | 2 | 2018 | 197 | 0.530 |
Why?
|
| Models, Educational | 1 | 2017 | 22 | 0.530 |
Why?
|
| Nephrectomy | 3 | 2018 | 37 | 0.490 |
Why?
|
| Image-Guided Biopsy | 3 | 2019 | 34 | 0.420 |
Why?
|
| Prostatectomy | 4 | 2012 | 20 | 0.410 |
Why?
|
| Humans | 25 | 2019 | 23187 | 0.380 |
Why?
|
| Nephrons | 1 | 2012 | 6 | 0.370 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2012 | 10 | 0.370 |
Why?
|
| Male | 19 | 2019 | 12659 | 0.360 |
Why?
|
| Neoplasms, Second Primary | 1 | 2012 | 36 | 0.360 |
Why?
|
| Urologic Diseases | 1 | 2011 | 5 | 0.360 |
Why?
|
| Sarcoidosis | 1 | 2011 | 13 | 0.350 |
Why?
|
| Marital Status | 1 | 2010 | 9 | 0.330 |
Why?
|
| Middle Aged | 14 | 2019 | 7981 | 0.330 |
Why?
|
| Insurance, Liability | 1 | 2010 | 1 | 0.330 |
Why?
|
| Testicular Neoplasms | 1 | 2010 | 20 | 0.330 |
Why?
|
| Penile Neoplasms | 1 | 2008 | 1 | 0.280 |
Why?
|
| Lymph Node Excision | 1 | 2008 | 26 | 0.280 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2019 | 875 | 0.260 |
Why?
|
| Postoperative Complications | 3 | 2018 | 812 | 0.260 |
Why?
|
| Retrospective Studies | 7 | 2018 | 2993 | 0.260 |
Why?
|
| Ultrasonography | 2 | 2019 | 203 | 0.250 |
Why?
|
| United States | 5 | 2015 | 1803 | 0.250 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2004 | 111 | 0.250 |
Why?
|
| Liability, Legal | 1 | 2006 | 2 | 0.240 |
Why?
|
| Female | 9 | 2019 | 13142 | 0.240 |
Why?
|
| Biopsy, Needle | 2 | 2005 | 101 | 0.240 |
Why?
|
| Aged | 10 | 2018 | 7660 | 0.230 |
Why?
|
| Pneumothorax | 1 | 2005 | 4 | 0.220 |
Why?
|
| Adenocarcinoma | 2 | 2003 | 135 | 0.220 |
Why?
|
| Unnecessary Procedures | 1 | 2005 | 26 | 0.220 |
Why?
|
| Genes, erbB-2 | 1 | 2004 | 7 | 0.210 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2004 | 19 | 0.210 |
Why?
|
| Receptor, ErbB-2 | 1 | 2004 | 52 | 0.210 |
Why?
|
| Multivariate Analysis | 4 | 2013 | 288 | 0.200 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 1 | 2003 | 1 | 0.190 |
Why?
|
| Prostatic Hyperplasia | 1 | 2003 | 13 | 0.190 |
Why?
|
| Genital Neoplasms, Male | 1 | 2002 | 1 | 0.190 |
Why?
|
| Seminal Vesicles | 1 | 2002 | 2 | 0.190 |
Why?
|
| Rectum | 3 | 2018 | 50 | 0.190 |
Why?
|
| Glycoproteins | 1 | 2003 | 41 | 0.190 |
Why?
|
| Neurilemmoma | 1 | 2002 | 12 | 0.190 |
Why?
|
| Adult | 6 | 2018 | 6959 | 0.190 |
Why?
|
| Proportional Hazards Models | 3 | 2013 | 279 | 0.190 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2018 | 52 | 0.170 |
Why?
|
| Time Factors | 2 | 2017 | 1264 | 0.170 |
Why?
|
| Survival Rate | 2 | 2012 | 320 | 0.160 |
Why?
|
| Ultrasonography, Interventional | 2 | 2018 | 64 | 0.150 |
Why?
|
| Neoplasm Invasiveness | 1 | 2019 | 88 | 0.150 |
Why?
|
| Fluoroquinolones | 1 | 2018 | 12 | 0.140 |
Why?
|
| Phantoms, Imaging | 1 | 2018 | 33 | 0.140 |
Why?
|
| Ovariectomy | 1 | 2018 | 26 | 0.140 |
Why?
|
| Hysterectomy | 1 | 2018 | 25 | 0.140 |
Why?
|
| Ureter | 1 | 2018 | 27 | 0.140 |
Why?
|
| Preoperative Period | 1 | 2018 | 65 | 0.140 |
Why?
|
| Treatment Failure | 1 | 2018 | 126 | 0.140 |
Why?
|
| Risk Factors | 3 | 2018 | 2020 | 0.140 |
Why?
|
| Biopsy, Large-Core Needle | 1 | 2017 | 6 | 0.130 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2017 | 26 | 0.130 |
Why?
|
| Early Detection of Cancer | 1 | 2018 | 100 | 0.130 |
Why?
|
| Renal Veins | 1 | 2017 | 2 | 0.130 |
Why?
|
| Surgical Stapling | 1 | 2017 | 4 | 0.130 |
Why?
|
| Renal Artery | 1 | 2017 | 6 | 0.130 |
Why?
|
| Surgical Wound Infection | 1 | 2017 | 76 | 0.120 |
Why?
|
| Self Report | 1 | 2017 | 202 | 0.120 |
Why?
|
| Attitude of Health Personnel | 1 | 2017 | 134 | 0.120 |
Why?
|
| Anti-Bacterial Agents | 1 | 2018 | 363 | 0.120 |
Why?
|
| Laparoscopy | 1 | 2017 | 185 | 0.110 |
Why?
|
| Follow-Up Studies | 3 | 2018 | 1430 | 0.110 |
Why?
|
| Prostate-Specific Antigen | 2 | 2005 | 15 | 0.110 |
Why?
|
| Lung Neoplasms | 1 | 2018 | 539 | 0.100 |
Why?
|
| Hernia, Inguinal | 1 | 2013 | 18 | 0.100 |
Why?
|
| Comorbidity | 3 | 2018 | 429 | 0.100 |
Why?
|
| Melanoma | 1 | 2013 | 49 | 0.100 |
Why?
|
| Kidney | 1 | 2013 | 142 | 0.090 |
Why?
|
| Radiotherapy | 1 | 2012 | 30 | 0.090 |
Why?
|
| Genital Diseases, Male | 1 | 2011 | 6 | 0.090 |
Why?
|
| Survival Analysis | 1 | 2012 | 226 | 0.090 |
Why?
|
| Young Adult | 2 | 2017 | 1657 | 0.090 |
Why?
|
| Combined Modality Therapy | 1 | 2012 | 294 | 0.090 |
Why?
|
| Kidney Diseases | 1 | 2011 | 69 | 0.080 |
Why?
|
| Pyrimidines | 1 | 2010 | 24 | 0.080 |
Why?
|
| Prognosis | 2 | 2010 | 730 | 0.080 |
Why?
|
| Rectal Neoplasms | 1 | 2010 | 15 | 0.080 |
Why?
|
| Incidence | 3 | 2018 | 633 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2010 | 168 | 0.080 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2010 | 30 | 0.080 |
Why?
|
| Piperazines | 1 | 2010 | 83 | 0.080 |
Why?
|
| Antineoplastic Agents | 1 | 2010 | 194 | 0.070 |
Why?
|
| Aged, 80 and over | 3 | 2018 | 3865 | 0.070 |
Why?
|
| Physical Examination | 2 | 2005 | 87 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2018 | 578 | 0.060 |
Why?
|
| Treatment Outcome | 3 | 2017 | 2943 | 0.060 |
Why?
|
| Cystectomy | 1 | 2006 | 8 | 0.060 |
Why?
|
| Urination Disorders | 1 | 2005 | 7 | 0.060 |
Why?
|
| Auscultation | 1 | 2005 | 2 | 0.060 |
Why?
|
| Respiratory Sounds | 1 | 2005 | 5 | 0.060 |
Why?
|
| Pleura | 1 | 2005 | 8 | 0.060 |
Why?
|
| Case Management | 1 | 2005 | 7 | 0.060 |
Why?
|
| Radiography, Thoracic | 1 | 2005 | 24 | 0.060 |
Why?
|
| Catheterization, Central Venous | 1 | 2005 | 34 | 0.050 |
Why?
|
| Intraoperative Complications | 1 | 2005 | 56 | 0.050 |
Why?
|
| Biopsy | 2 | 2018 | 188 | 0.050 |
Why?
|
| Gene Amplification | 1 | 2004 | 21 | 0.050 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2004 | 37 | 0.050 |
Why?
|
| Urinary Bladder | 1 | 2004 | 18 | 0.050 |
Why?
|
| Sensitivity and Specificity | 1 | 2005 | 445 | 0.050 |
Why?
|
| Immunohistochemistry | 1 | 2004 | 338 | 0.050 |
Why?
|
| Androgen Antagonists | 1 | 2003 | 4 | 0.050 |
Why?
|
| Length of Stay | 1 | 2005 | 298 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 1 | 2003 | 164 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2003 | 314 | 0.040 |
Why?
|
| Surveys and Questionnaires | 1 | 2006 | 1037 | 0.040 |
Why?
|
| Education | 1 | 2019 | 31 | 0.040 |
Why?
|
| False Positive Reactions | 1 | 2018 | 29 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2018 | 50 | 0.040 |
Why?
|
| Bacterial Infections | 1 | 2018 | 47 | 0.030 |
Why?
|
| Lung | 1 | 2018 | 139 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2018 | 238 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2018 | 369 | 0.030 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2017 | 82 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2018 | 353 | 0.030 |
Why?
|
| Arteriovenous Fistula | 1 | 2017 | 10 | 0.030 |
Why?
|
| Ligation | 1 | 2017 | 36 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 235 | 0.030 |
Why?
|
| Operative Time | 1 | 2017 | 81 | 0.030 |
Why?
|
| Linear Models | 1 | 2013 | 202 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2013 | 550 | 0.020 |
Why?
|
| Imatinib Mesylate | 1 | 2010 | 8 | 0.020 |
Why?
|
| Benzamides | 1 | 2010 | 13 | 0.020 |
Why?
|
| Colectomy | 1 | 2010 | 20 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 1 | 2010 | 61 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2005 | 442 | 0.010 |
Why?
|
| Age Factors | 1 | 2005 | 651 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2005 | 1512 | 0.010 |
Why?
|